Back

Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death

25 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulation in patients with atrial fibrillation Anticoagulants ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Mr Maxim Grymonprez

University Hospital Ghent, Gent (Belgium)

7 More presentations in this session

Presentation thumbnail
Ischemic and non-ischemic stroke reported in DOAC treated patients with atrial fibrillation and levetiracetam drug interaction: a real-world study
Doctor M. Abou Kaoud (Tel Aviv, IL)
Abstract Slides
Presentation thumbnail
Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation
Doctor S. Deitelzweig (New Orleans, US)
Abstract Slides Video
Presentation thumbnail
Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin
Doctor S. Patel (Boston, US)
Abstract Slides Video
Presentation thumbnail
Comparisons of effectiveness and safety between different dosage strategy in patients with atrial fibrillation treated with rivaroxaban: a systemic review and meta-analysis
Doctor T. Chao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Comparison of baseline characteristics and outcomes of on-label full dose (20mg) and off-label reduced dose (15mg) rivaroxaban in patients with atrial fibrillation in Asian elderly patients
Doctor J. Kim (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Oral anticoagulation in patients with atrial fibrillation

The Event

Event poster

ESC Congress 2023

25 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial.
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
thumbnail
Congress Presentation
Temporal trends of prescription rates, dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in patients with atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources